Skip to main content
Mary-Ellen Taplin, MD, Oncology, Boston, MA

Mary-EllenTaplinMD

Oncology Boston, MA

Associate Professor of Medicine, Dana-Farber Cancer Institute

Dr. Taplin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Taplin's full profile

Already have an account?

  • Office

    450 Brookline Ave
    D1230
    Boston, MA 02115
    Phone+1 617-582-7221
    Fax+1 617-632-2165

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
  • UMass Chan Medical School
    UMass Chan Medical SchoolResidency, Internal Medicine, 1986 - 1990
  • University of Massachusetts Medical School
    University of Massachusetts Medical SchoolClass of 1986

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1987 - 2025
  • NH State Medical License
    NH State Medical License 2023 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • Boston Magazine Castle Connolly, 2008-2013
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to ... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Optimizing Androgen Receptor Targeting Strategies Perspective 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Other

Authored Content

  • Clinical and Genomic Characterization of Low–Prostate-Specific Antigen, High-Grade Prostate CancerFebruary 2018

Press Mentions

  • Neoadjuvant NHAs Followed by Surgery Can Improve Key Outcomes in High-Risk Prostate Cancer Patients
    Neoadjuvant NHAs Followed by Surgery Can Improve Key Outcomes in High-Risk Prostate Cancer PatientsSeptember 12th, 2022
  • The Prostate Cancer Foundation Announces First Ever Pcf-Pfizer Global Health Equity Challenge Award Winners
    The Prostate Cancer Foundation Announces First Ever Pcf-Pfizer Global Health Equity Challenge Award WinnersApril 29th, 2022
  • Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in Practice
    Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022
  • Join now to see all

Professional Memberships